Citation Impact
Citing Papers
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Point-of-Care Testing
2012 Standout
Homocysteine and vascular disease
1999 Standout
The Metabolic Syndrome and Inflammation
2004
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2007
Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals
2006
Thiazolidinediones
2004 Standout
Hyperhomocysteinaemia
1999
Short-Term Effects of Nose-Only Cigarette Smoke Exposure on Glutathione Redox Homeostasis, Cytochrome P450 1A1/2 and Respiratory Enzyme Activities in Mice Tissues
2013 Standout
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
New oral antithrombotics: a need for laboratory monitoring. For
2010
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
2002 Standout
Bivalirudin during Primary PCI in Acute Myocardial Infarction
2008 Standout
Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non–ST-Segment Elevation Acute Coronary Syndromes
2005
Oral Anticoagulant Therapy
2012 Standout
The metabolic syndrome
2010 Standout
Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention
2007
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction
2006 Standout
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
2003
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
2005
Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance
2000
Effects of extracellular matrix viscoelasticity on cellular behaviour
2020 StandoutNature
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
2001
Thyroid Hormone and the Cardiovascular System
2001 Standout
A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease
1995 Standout
Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction
2006 Standout
MTHFR 677C→T Polymorphism and Risk of Coronary Heart Disease
2002
Coagulation markers in healthy human subjects exposed to diesel exhaust
2007
Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: Results of the STACK-on to ENOXaparin (STACKENOX) study
2009
The metabolic syndrome
2005 Standout
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale
2004
Homocysteine and Risk of Ischemic Heart Disease and Stroke
2002 Standout
Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study
2004
Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease
2002
The Year in Non–ST-Segment Elevation Acute Coronary Syndrome
2010
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
2004 Standout
Guidelines for Percutaneous Coronary Interventions
2005
Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials
2008
A Simplified Approach to the Management of Non–ST-Segment Elevation Acute Coronary Syndromes
2005
Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention
2010
Prevalence of familial mild hyperhomocysteinemia
1996
Transcoronary Transplantation of Progenitor Cells after Myocardial Infarction
2006 Standout
Thrombotic Markers in Metabolic Syndrome Subjects Exposed to Diesel Exhaust
2008
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
2006
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
2008
Aspirin Dose for the Prevention of Cardiovascular Disease
2007
Meta-analysis of Hyperhomocysteinemia as a Risk Factor for Venous Thromboembolic Disease
1998
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis?
1995
Fibrinogen and fibrin: scaffold proteins in hemostasis
2007
Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes
2009
The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI
2000 Standout
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Antithrombotic Therapy During Percutaneous Coronary Intervention
2004
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial
2004 Standout
Degree of Anticoagulation after One Subcutaneous and One Subsequent Intravenous Booster Dose of Enoxaparin: Implications for Patients with Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention
2004
Homocysteine and Atherothrombosis
1998 Standout
Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis
1996
Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
2007
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial
2009
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study
2008
Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery
2009
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
2007 Standout
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
2005 Standout
Extracellular DNA traps promote thrombosis
2010 Standout
Plasma Homocysteine Levels in Patients With Deep Venous Thrombosis
1995
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Hyperhomocysteinemia, Atherosclerosis and Thrombosis
1999
High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.
1994
Vascular damage from smoking: disease mechanisms at the arterial wall
1998
Markers of Inflammation and Cardiovascular Disease
2003 Standout
Regulatory T Cells Control PF4/Heparin Antibody Production in Mice
2019
PAI-1 and the Metabolic Syndrome
2006
Subclinical Hypothyroidism Is an Independent Risk Factor for Atherosclerosis and Myocardial Infarction in Elderly Women: The Rotterdam Study
2000
Luminescent Chemodosimeters for Bioimaging
2012 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary
2014
Regulation of Plasma PAI-1 Concentrations in HAART-Associated Lipodystrophy During Rosiglitazone Therapy
2003
Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding
2009
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Homocysteine and Thrombotic Disease
1997
Hyperhomocysteinemia and Venous Thrombosis
2007
von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects
1999
Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease
2006 Standout
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events
2004
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence
1999
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Particulate Matter Air Pollution and Cardiovascular Disease
2010 Standout
Anticoagulation in Pregnant Women With Prosthetic Heart Valves
2004
Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial Infarction
1999
Homocysteine and Cardiovascular Disease
1998 Standout
Detection of Homocysteine and Cysteine
2005
Venous thrombosis: a multicausal disease
1999 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2011
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation
2003
Design Strategies for Water-Soluble Small Molecular Chromogenic and Fluorogenic Probes
2013 Standout
First-line Therapy with Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood Transfusion in Cardiovascular Surgery
2011
Weekend versus Weekday Admission and Mortality from Myocardial Infarction
2007 Standout
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction
2013
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Works of Annick Ankri being referenced
Does the polymorphism 677C‐T of the 5,10‐methylenetetrahydrofolate reductase gene contribute to homocysteine‐related vascular disease?
1998
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention
2002
Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome
2005
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials
2002
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
2000
Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients*
1998
Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease
1997
Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters
1993
Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Bedside Test
2010
Changes in Enoxaparin Pharmacokinetics During Pregnancy and Implications for Antithrombotic Therapeutic Strategy
2008
Anti‐factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis
2005
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes
2004
Mécanismes et prédiction des complications hémorragiques au cours de la chirurgie des anévrysmes de l'aorte thoracoabdominale
1990
Fibrinogen After Coronary Angioplasty as a Risk Factor for Restenosis
1995
Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin
2004
Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity?
1995
[Plasma homocysteine assay in the exploration of thrombosis in young subjects].
1991
Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris.
1991
Relationship between Thyroid Hormones and Plasma D-dimer Levels
1998
Relation between Plasminogen Activator Inhibitor-1 and Hepatic Enzyme Concentrations in Hyperlipidemic Patients
1994
Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality
2003
Early Increase of von Willebrand Factor Predicts Adverse Outcome in Unstable Coronary Artery Disease
1998
Altered Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis
2006
Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery
2009
Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris
2001
Hgh prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia
2007
Evidence for a relationship between plasminogen activator inhibitor-1 and gamma glutamyl transferase
1996